Eribulin mesylate: Phase III data

The open-label, international Phase III Study 309 in 452 STS patients ages >=18 showed that 1.4 mg/m 2

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE